TrialThe lancet. HIV2020

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.

Kenneth Kintu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.